Drug Profile
Research programme: eosinophilic oesophagitis therapeutic - Adare Pharmaceuticals
Latest Information Update: 30 Sep 2015
Price :
$50
*
At a glance
- Originator Aptalis
- Developer Adare Pharmaceuticals
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Oesophagitis
Most Recent Events
- 30 Sep 2015 No development reported for Oesophagitis in Canada (PO)
- 02 Apr 2015 Aptalis Pharmaceuticals has been acquired by TGP and renamed Adare Pharmaceuticals
- 03 Feb 2014 Aptalis has been acquired by Forest Laboratories